Bayer Intellectual Property Gmbh

Bayer Pharma Aktiengesellschaft

Jörg Fanghänel

Philip Lienau

Knut Eis

Mark Jean Gnoth

Gerhard Siemeister

Ulf Bömer

Hans Briem

Ludwig Zorn

Arne Scholz

Antje Margret Wengner

Anne Mengel

Volker Schulze

Judith Günther

Simon Holton

Amaury Ernesto Fernandez-Montalvan

Marion Hitchcock

Stefan Prechtl

Florian Pühler

Daniel Korr

Vera Pütter

Cornelia Preusse

Compounds of formula (I) which are inhibitors of Bub 1 kinase, processes for their production and their use as pharmaceuticals.

Substituted benzylindazoles for use as BUB1 kinase inhibitors in the treatment of hyperproliferative diseases

Substituted benzylindazoles for use as Bub1 kinase inhibitors in the treatment of hyperproliferative diseases

The present invention relates to substituted aminoimidazopyridazine compounds of general formula (I): in which A, R1, R2, R3 and R4 are as defined in the claims, to methods of preparing said compounds, to pharmaceutical compositions and combinations comprising said compounds and to the use of said compounds for manufacturing a pharmaceutical composition for the treatment or prophylaxis of a disease, in particular of a hyper-proliferative and/or angiogenesis disorder, as a sole agent or in combination with other active ingredients. 

Substituted aminoimidazopyridazines

The present invention relates to heterocyclyl aminoimidazopyridazine compounds of general formula (I): in which A, R1, R2, R3 and R4 are as defined in the claims, to methods of preparing said compounds, to pharmaceutical compositions and combinations comprising said compounds and to the use of said compounds for manufacturing a pharmaceutical composition for the treatment or prophylaxis of a disease, in particular of a hyper-proliferative and/or angiogenesis disorder, as a sole agent or in combination with other active ingredients. 

Heterocyclyl aminoimidazopyridazines

Growing community of inventors

Berlin, Germany

Jörg Fanghänel